China (Mainland)
Premiumsupplier 
110078-46-1PLERIXAFORPLERIXAFOR CAS NO.110078-46-1
- Min.Order: 1 Kilogram
- Payment Terms: L/C,D/A,D/P,T/T,
- Product Details
Keywords
- 110078-46-1
- PLERIXAFOR
- C28H54N8
Quick Details
- ProName: 110078-46-1PLERIXAFORPLERIXAFOR
- CasNo: 110078-46-1
- Molecular Formula: C28H54N8
- Appearance: White or off-white Solid
- Application: intermediate
- DeliveryTime: 20day
- PackAge: According to the demand of customer
- Port: shanghai
- ProductionCapacity: 20 Metric Ton/Day
- Purity: 99.0%
- Storage: Sealed, dry, microtherm , avoid light ...
- Transportation: According to the demand of customer
- LimitNum: 1 Kilogram
- Grade: Industrial Grade,Pharma Grade,Electron...
Superiority
Good quality
Good price
Promptly delivery
Details
| PLERIXAFOR Basic information |
| Product Name: | PLERIXAFOR |
| Synonyms: | PLERIXAFOR;1,1'-[1,4-Phenylenebis(methylene)]bis-1,4,8,11-tetraazacyclotetradecane;1,4,8,11-Tetraazacyclotetradecane, 1,1'-(1,4-phenylenebis(methylene))bis-;Mozobil;Sdz sid 791;Unii-S915p5499n;1-[[4-(1,4,8,11-tetrazacyclotetradec-1-ylmethyl)phenyl]methyl]-1,4,8,11-tetrazacyclotetradecane;Plerixafor(AMD3100) |
| CAS: | 110078-46-1 |
| MF: | C28H54N8 |
| MW: | 502.791 |
| EINECS: | |
| Product Categories: | Aromatics;Heterocycles;Inhibitors;Intermediates & Fine Chemicals;Pharmaceuticals |
| Mol File: | 110078-46-1.mol |
|
|
|
| PLERIXAFOR Chemical Properties |
| mp | 122-125°C |
| density | 0.962 |
| storage temp. | Refrigerator |
| Safety Information |
| PLERIXAFOR Usage And Synthesis |
| Chemical Properties | White Solid |
| Usage | Plerixafor is a chemokine receptor antagonist for CXCR4 and CXCL12-mediated chemotaxis with IC50 of 44 nM and 5.7 nM, respectively |
| Usage | Plerixafor is a hematopoietic stem cell (HSC) mobilizer that inhibits the CXCR4 chemokine receptor and blocks binding of its ligand, stromal cell-derived factor-1-α (SDF-1-α). on Dec. 15, 2008, as treatment in combination with granulocyte-colony stimulating factor (G-CSF) to mobilize HSCs to the peripheral blood for collection and subsequent autologous transplantation in p atients with non-Hodgkin's lymphoma (NHL) and multiple myeloma (MM). |